✨ Free AI Report
AngioDynamics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research AngioDynamics, Inc.
Company Research

AngioDynamics, Inc.: Business Overview, Financials & Competitive Analysis

AngioDynamics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Undervalued high-growth MedTech platform after strategic transformation driving 20%+ Med Tech growth, improving profitability, and debt-free operations, trading at steep valuation discount to peers. The Med Tech segment showed exceptional performance with 26.1% growth to $35.3 million, marking its fourth consecutive quarter of over 20% growth. Gross margin for the.

What is AngioDynamics, Inc.'s industry? AngioDynamics, Inc. (angiodynamics.com) operates in Medical Devices - Minimally Invasive Surgery and Interventional Medicine. AskCyborg classifies AngioDynamics, Inc. under Medical Devices - Minimally Invasive Surgery and Interventional Medicine in its company registry.

AngioDynamics, Inc. (NASDAQ: ANGO), is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options. In Q1 FY2026, the company reported net sal...

7/ 10Strong

Cyborg Score thesis

Undervalued high-growth MedTech platform after strategic transformation driving 20%+ Med Tech growth, improving profitability,...

Read the full analyst-debate transcript →
Industry Medical Devices - Minimally Invasive Surgery and Interventional Medicine
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest AngioDynamics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for AngioDynamics, Inc.

AskCyborg analysts argue the bull and bear cases for AngioDynamics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
AngioDynamics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

AngioDynamics, Inc. Overview

Pro stress-test →

AngioDynamics, Inc. (NASDAQ: ANGO), is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options. In Q1 FY2026, the company reported net sales of $75.7 million, up 12.2% year-over-year, with exceptional growth in its high-margin Med Tech platforms.

Strategic Profile

Pro stress-test →

AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. The Med Tech segment showed exceptional performance with 26.1% growth, marking its fourth consecutive quarter of over 20% growth. The company maintains a debt-free balance sheet and is transitioning toward profitability with improving gross margins and positive cash flow expectations.

Competitive Landscape

Pro stress-test →

AngioDynamics competes in peripheral vascular disease and oncology markets with differentiated products including the Auryon Atherectomy system for lesion removal, thrombus management portfolio (AlphaVac, AngioVac), and NanoKnife IRE ablation system. Key competitors include AtriCure, Merit Medical Systems, and larger diversified medtech players. The company's focus on minimally invasive platforms with strong clinical support positions it favorably in growing interventional markets.

Industry Context

AngioDynamics, Inc. operates in Medical Devices - Minimally Invasive Surgery and Interventional Medicine.

Key facts

Headquarters: Latham, New York · Revenue: $312-314M (FY2026E) · Market cap: $522-545M

What the analysts stress-tested

The top findings that survived the multi-agent debate for AngioDynamics, Inc..

  • Med Tech segment now drives significant growth with 26.1% YoY expansion in Q1 FY2026, markedly outpacing overall company growth of 12.2%
  • Gross margin expansion of 90-260 basis points driven by higher-margin Med Tech mix and operational efficiencies despite tariff headwinds
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026FDA IDE approval for APEX-Return study and PAVE clinical study; modified AlphaVac F1885 510(k) clearance
  • January 2026Concluded long-standing patent litigation with Bard; raised FY2026 revenue guidance to $312-314M
  • +2 moreTrack every material event for AngioDynamics, Inc. as it happens. Explore monitoring →
Get alerted when AngioDynamics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Auryon Atherectomy SystemCompeting atherectomy platform for peripheral vascular disease→Mechanical thrombectomy systemsCompeting mechanical aspiration and removal systems for clot management→Irreversible electroporation ablationNiche competitor with established NanoKnife platform for soft tissue ablation→

Compare AngioDynamics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

AngioDynamics, Inc. operates in Medical Devices - Minimally Invasive Surgery and Interventional Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Minimally Invasive Surgery and Interventional Medicine research →
NEW · MCP server

Ask your AI assistant about AngioDynamics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare AngioDynamics, Inc. and its top competitor on Cyborg Score”
“What did AngioDynamics, Inc. do this quarter?”
“Is AngioDynamics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does AngioDynamics, Inc. do?+
AngioDynamics, Inc. (NASDAQ: ANGO), is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options. In Q1 FY2026, the company reported net sal...
What is AngioDynamics, Inc.'s Cyborg Score?+
AngioDynamics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are AngioDynamics, Inc.'s main competitors?+
Named competitors include Auryon Atherectomy System, Mechanical thrombectomy systems, Irreversible electroporation ablation. The full competitive landscape is in the AskCyborg report.
How can I get the full AngioDynamics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the AngioDynamics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track AngioDynamics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.